ImmuCell (NASDAQ:ICCC - Get Free Report) announced its earnings results on Thursday. The biotechnology company reported $0.06 EPS for the quarter, Zacks reports. The business had revenue of $6.45 million for the quarter. ImmuCell had a net margin of 6.23% and a return on equity of 6.25%.
ImmuCell Stock Performance
ICCC traded down $0.21 during trading on Tuesday, hitting $5.90. The stock had a trading volume of 11,348 shares, compared to its average volume of 12,585. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.21 and a current ratio of 3.85. The firm has a market capitalization of $53.34 million, a P/E ratio of 31.05 and a beta of 0.30. The company's 50-day moving average price is $6.52 and its 200 day moving average price is $5.77. ImmuCell has a twelve month low of $3.34 and a twelve month high of $7.60.
Hedge Funds Weigh In On ImmuCell
An institutional investor recently raised its position in ImmuCell stock. Geode Capital Management LLC raised its position in ImmuCell Corporation (NASDAQ:ICCC - Free Report) by 4.2% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 71,852 shares of the biotechnology company's stock after buying an additional 2,907 shares during the quarter. Geode Capital Management LLC owned about 0.79% of ImmuCell worth $500,000 as of its most recent filing with the SEC. Institutional investors own 13.47% of the company's stock.
ImmuCell Company Profile
(
Get Free Report)
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.
See Also
Before you consider ImmuCell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuCell wasn't on the list.
While ImmuCell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
